Tenth wave of Ebola epidemic defeated with vaccine

virus Ebola in the Democratic Republic of Congo (DRC), after 42 consecutive days with no new cases. The epidemic, which started almost two years ago, in August 2018, in the province of North Kivu, affected 3,470 people and left 2,287 dead (or a fatality rate of 66%) and 1,171 survivors. “data-reactid =” 12 “> On June 25, the World Organization Health (WHO) announced the end of the tenth epidemic of the virus Ebola in the Democratic Republic of Congo (DRC), after 42 consecutive days with no new cases. The epidemic, which started almost two years ago, in August 2018, in the province of North Kivu, affected 3,470 people and left 2,287 dead (a fatality rate of 66%) and 1,171 survivors.

For the first time, the Congolese government, supported by WHO, has launched a massive vaccination and follow-up campaign for cured patients. Thanks to this, the number of cases has been limited.

A simple scheme of the modified virus used in the rVSV-ZEBOV vaccine. It is the vesicular stomatitis virus (VSV) in which its native surface glycoprotein has been replaced by those of Ebola. © Based on Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine

Over 300,000 people vaccinated

During the 22 months that lasted the epidemic, the nursing staff recorded 250,000 contact cases and preemptively tested a large part of them (230,000 people tested). This effort to prevent the spread of the epidemic was complemented by an extensive vaccination campaign: 303,000 people received an injection of the rVSV-ZEBOV-GP vaccine.

Read Also:  Gyms and swimming pools towards confirmation of closure, the managers write to Draghi

Towards a universal Ebola vaccine?” data-reactid=”27″>Towards a universal Ebola vaccine?

A clinical trial carried out in 2015 indicates that the vaccine efficacy of rVSV-ZEBOV-GP is between 70 to 100%. The latter is effective against the Zaire strain of the virus, which is at the origin of this epidemic outbreak. “Data-reactid =” 28 “> Behind this complicated name hides a recombinant vaccine developed by Canadian researchers and marketed by Merck: Each vaccine dose contains the vesicular stomatitis virus, a rhabdovirus, modified to express the surface glycoprotein of the Ebola virus, one dose is enough to induce sufficiently strong and long-lasting immunity against Ebola. A clinical trial carried out in 2015 indicates that the vaccine efficacy of rVSV-ZEBOV-GP is between 70 to 100%. The latter is effective against the Zaire strain of the virus, which is at the origin of this epidemic outbreak.

> Read more on Futura” data-reactid=”30″>> Read more on Futura

Share on facebook
Facebook
Share on pinterest
Pinterest
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Trending